Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Atalanta Therapeutics

Request full access

Pioneering RNAi treatments for neurodegenerative diseases

Boston, United StatesFounded 2018Biotech & Life Sciences

About Atalanta Therapeutics

Atalanta Therapeutics is a pioneering biotechnology company specializing in RNA interference (RNAi) to develop groundbreaking gene silencing therapies. The company focuses on creating branched small interfering RNA (siRNA) molecules that can halt diseases at their genetic source. Atalanta's primary clients include pharmaceutical companies and research institutions seeking advanced therapeutic solutions for genetic disorders. Operating in the biopharmaceutical market, Atalanta employs a business model centered on research and development, clinical trials, and strategic partnerships. Revenue is generated through licensing agreements, research collaborations, and milestone payments from successful clinical advancements. The company's innovative approach leverages Nobel Prize-winning science to offer a powerful therapeutic strategy for treating a wide range of diseases.

Source: Dealroom company data

At a glance

Status
Operational
Employees
39
Open positions
1
Dealroom signal
62.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Neurology, Genetics and genomics, Degenerative Diseases, RNA, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2025 $97M $388M RiverVest Venture Partners · Pictet · F-Prime · GHR Foundation ↗
SERIES AOther financing Jan 2021 $110M $440M F-Prime —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Atalanta Therapeutics website traffic

Latest recorded traffic for Atalanta Therapeutics is 2.6K monthly website visits, down 23.5% over the last three months. Atalanta Therapeutics's team declined 32.8% over the past year.

Latest monthly visits2.6K 3-month web change-23.5% 1-year team growth-32.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Atalanta Therapeutics in the Boston ecosystem

Live from Dealroom

The Atalanta Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • F-Prime
  • EQT Life Sciences
  • Sanofi Ventures
  • RiverVest Venture Partners
  • Pictet
  • GHR Foundation
  • Mirae Asset Capital
  • Novartis Venture Fund
  • Aberdeen

Other known investors1 additional known investor

  • University of Massachusetts Medical School
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States97.8%
🇳🇱 Netherlands2.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Atalanta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Atalanta Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.